Fruquintinib Gives PFS Boost in Gastric Cancers Free

The combination of Takeda’s fruquintinib (Fruzaqla) plus paclitaxel significantly improved progression-free survival compared with placebo plus paclitaxel—5.6 vs. 2.7 months, respectively—in patients with advanced stomach cancers that progressed while on or after receiving first-line chemotherapy. However, in presenting findings of the FRUTIGA trial during the February 2024 session of the American Society of Clinical Oncology Plenary Series, researchers said that the improvement in overall survival—9.6 months vs. 8.4 months, respectively—was not statistically significant. Fruquintinib, a VEGFR 1/2/3 inhibitor, was approved in November 2023 for the treatment of certain metastatic colorectal cancers.